<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122784">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02007772</url>
  </required_header>
  <id_info>
    <org_study_id>TIBICO</org_study_id>
    <nct_id>NCT02007772</nct_id>
  </id_info>
  <brief_title>Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients</brief_title>
  <acronym>TIBICO</acronym>
  <official_title>Effectiveness of TNI (Nasal High-flow) vs. BiPAP (Biphasic Positive Airway Pressure) in Chronic Global Insufficiency in COPD (Chronic Obstructive Pulmonary Disease) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TNI Medical AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial ist to investigate the difference of the efficacy of two systems
      for breath support in patients with COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial consists of 12 weeks of therapy that is divided into two sections. In the first
      6-week section patients receive treatment with either TNI or BiPAP and in the second 6-week
      section treatment is changed. The starting therapy is allocated to the patients via
      randomisation and should be started directly after the baseline visit.

      The treatment and the follow-up period end with the second visit after the second treatment
      section and the patient decides which device he/she wants to use further.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>difference in capillary CO2 carbon dioxide</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint is the difference of the relative decrease of capillary pC02 after the treatment with nasal high-flow compared with the baseline value and the relative decrease of the capillary pCO2 after treatment with BiPAP compared with the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference in absolute change of capillary pCO2 (partial pressure of carbon dioxide ) compared with baseline</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of occurrence of normocapnia after intervention</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Normocapnia is therefore defined as capillary pCO2 &lt;= 45 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the relative and absolute change of capillary pCO2 compared with baseline</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the absolute change of SaO2 (arterial oxygen saturation) compared with baseline</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the absolute and relative change of base excess compared with baseline</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the values of base excess after treatment with nHF (nasal high-flow) and of base excess after treatment with BiPAP</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the absolute change of HCO3- (hydrogen carbonate / bicarbonate) compared with baseline</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of HCO3- after treatment with nHF and of HC03- after treatment with BiPAP</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of P0,1 after treatment with nHF and of P0,1 after treatment with BiPAP</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of PImax after treatment with nHF and of PImax (maximal inspiratory pressure) after treatment with BiPAP</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of P0,1/PImax after treatment with nHF and of P0,1/PImax after treatment with BiPAP</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the absolute change of the results of the 6-minutes walking test compared with baseline</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the absolute change of the disease-specific quality of life compared to baseline</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life is measured by SGQR (The St George's Respiratory Questionnaire), SRI (Severe Respiratory Insufficiency Questionnaire), a VAS referring to the general health status and the Borg-Scale (CR 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of occurrence and type of adverse events under trial therapy (both arms)</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the values of user-friendliness of both devices</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the time both devices were used</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>COPD Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>BiPAP breathing support</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BiPAP is used over a period of 6 weeks (outpatient)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nHF / TNI breathing support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nasal high-flow is used over a period of 6 weeks (outpatient)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nHF</intervention_name>
    <description>nasal high-flow is used over a period of 6 weeks (outpatient)</description>
    <arm_group_label>BiPAP breathing support</arm_group_label>
    <arm_group_label>nHF / TNI breathing support</arm_group_label>
    <other_name>nasal high-flow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiPAP</intervention_name>
    <description>BiPAP is used over a period of 6 weeks (outpatient)</description>
    <arm_group_label>BiPAP breathing support</arm_group_label>
    <arm_group_label>nHF / TNI breathing support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of COPD with chronic respiratory global insufficiency

          -  chronic day-hypercapnia with pCO2 &gt;= 50 mmHg and typical symptoms of ventilatory
             insufficiency

          -  age 18 or older

          -  the patient or caretaker must be able to operate the device after a specific training

          -  patient must be willing to use the nHF-/BiPAP-device for the whole trial period for
             at least 5 hours/day

          -  patient must be able to answer the questionnaires

          -  written informed consent is obtained

        Exclusion Criteria:

          -  presence of acute respiratory insufficiency

          -  exacerbation of type I or II in the last 6 weeks

          -  conservative therapy including long-term oxygen therapy according to GOLD update 2011
             is not exhausted

          -  previous treatment with NIV (non-invasive ventilation)

          -  clinical instability or acute illness (e.g. acute myocardial infarction, tachycardial
             atrial fibrillation)

          -  signs of cardial decompensation (e.g. edema in the lower limbs, pleural effusion)

          -  other serious concomitant diseases, the assessment of eligibility is at the
             discretion of the investigator

          -  contraindications for NIV

          -  anamnestic suspicion or proven obstructive sleep apnea (OSA)

          -  relevant systemic infections, assessment of eligibility is at the discretion of the
             investigator

          -  BMI &gt; 30

          -  other additional pulmonary diseases of other genesis or diseases that affect
             breathing (e.g. mucoviscidosis, scoliosis, muscular diseases)

          -  lack of compliance

          -  participation in other interventional trials at the same time

          -  pregnant or nursing women

          -  fertile female patients without effective contraceptive measures during trial
             participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Braeunlich, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Faculty University Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Braeunlich, Dr.</last_name>
    <phone>+49-341-97</phone>
    <phone_ext>12450</phone_ext>
    <email>jens.braeunlich@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hubertus Wirtz, Prof. Dr.</last_name>
    <phone>+49-341-97</phone>
    <phone_ext>12600</phone_ext>
    <email>hubert.wirtz@medizin.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik Donaustauf, Zentrum für Pneumologie</name>
      <address>
        <city>Donaustauf</city>
        <state>Bayern</state>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Pfeifer, Prof. Dr.</last_name>
      <phone>+49-9403-80</phone>
      <phone_ext>215</phone_ext>
      <email>michael.pfeifer@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Michael Pfeifer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken München-Gauting, Klinik für Intensivmedizin und Langzeitbeatmung</name>
      <address>
        <city>Muenchen-Gauting</city>
        <state>Bayern</state>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Geiseler, Dr.</last_name>
      <phone>+49-89-85791</phone>
      <phone_ext>4300</phone_ext>
      <email>j.geiseler@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Jens Geiseler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim, Medizinische Klinik III, Pneumologie</name>
      <address>
        <city>Rosenheim</city>
        <state>Bayern</state>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Budweiser, PD Dr.</last_name>
      <phone>+49-8031-36 57</phone>
      <phone_ext>101</phone_ext>
      <email>stephan.budweiser@ro-med.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Budweiser, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Göttingen-Weende gGmbH, Abteilung für Pneumologie</name>
      <address>
        <city>Bovenden</city>
        <state>Niedersachsen</state>
        <zip>37120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl-Peter Criée, Prof. Dr.</last_name>
      <phone>+49-551--50 34 24 51</phone>
      <phone_ext>24 51</phone_ext>
      <email>criee@ekweende.de</email>
    </contact>
    <investigator>
      <last_name>Criée Carl-Peter, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinik Hagen-Ambrock, Pneumologie / Endoskopie</name>
      <address>
        <city>Hagen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58091</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Nilius, PD Dr.</last_name>
      <phone>+49-2331-974</phone>
      <phone_ext>2000</phone_ext>
      <email>georg.nilius@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Georg Nilius, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH, Thoraxchirurg. u Pneumolog.Klinik Köln- Merheim</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdel Hakim Bayarassou, Dr.</last_name>
      <phone>+49-221-890 718</phone>
      <phone_ext>928</phone_ext>
      <email>bayarassouh@kliniken-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Abdel Hakim Bayarassou, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Kloster Grafschaft GmbH, Schlafmedizin &amp; häusliche Beatmung</name>
      <address>
        <city>Schmallenberg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>57392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Dellweg, Dr.</last_name>
      <phone>+49-2972-791</phone>
      <phone_ext>00</phone_ext>
      <email>d.dellweg@fkkg.de</email>
    </contact>
    <investigator>
      <last_name>Dominic Dellweg, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonisches Werk Bethanien e.V, Klinik für Pneumologie</name>
      <address>
        <city>Solingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winfried Randerath, Prof. Dr.</last_name>
      <phone>+49-212-63</phone>
      <phone_ext>6002</phone_ext>
      <email>Randerath@klinik-bethanien.de</email>
    </contact>
    <investigator>
      <last_name>Winfried Randerath, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Department für Innere Medizin, Neurologie und Dermatologie</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Braeunlich, Dr.</last_name>
      <phone>+49-341-97-</phone>
      <phone_ext>12450</phone_ext>
      <email>jens.braeunlich@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Hubert Wirtz, Prof. Dr.</last_name>
      <phone>+49-341-97</phone>
      <phone_ext>12600</phone_ext>
      <email>hubert.wirtz@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Hubert Wirtz, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Braeunlich, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH, Klinik für Pneumologie</name>
      <address>
        <city>Bad Berka</city>
        <state>Thueringen</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reiner Bonnet, Prof. Dr.</last_name>
      <phone>+49-364-585</phone>
      <phone_ext>1501</phone_ext>
      <email>pne@zentralklinik.de</email>
    </contact>
    <investigator>
      <last_name>Reiner Bonnet, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Emil von Behring, Klinik für Pneumologie</name>
      <address>
        <city>Berlin</city>
        <zip>14165</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten-Gerriet Blum, Dr.</last_name>
      <phone>+49-30-810 22</phone>
      <phone_ext>339</phone_ext>
      <email>torsten-gerriet.blum@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Torsten-Gerriet Blum, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Harburg, Lungenheilkunde (Pneumologie) im Thoraxzentrum, Sektion Pneumologische Intensiv- u. Beatmungsmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>21079</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bachmann, Dr.</last_name>
      <phone>+49-40-181 88 64</phone>
      <phone_ext>575</phone_ext>
      <email>ma.bachmann@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Martin Bachmann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>September 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Jens Bräunlich, MD</investigator_full_name>
    <investigator_title>Dr. Jens Braeunlich</investigator_title>
  </responsible_party>
  <keyword>COPD, nHF, BiPAP</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
